DNL.L Share News (DNL)

DNL.L Information

There is currently no data for DNL

Diurnal's endocrine drug does not meet trial objective

Mon, 08th Oct 2018 09:29

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.Tested on 122 adults across seven countries with congenital adrenal hyperplasia who had been treated with combinations of generic steroids were randomised to either Chronocort on a twice-daily regime or continued their standard of care regimen.Chronocort achieved control on a lower overall dose of glucocorticoid with fewer patients requiring rescue therapy.A modified release formulation of Chronocort, designed to provide overnight cortisol release, eliminated the early morning peak in androgen levels seen using conventional therapy."We are surprised by these results," said Diurnal chief executive Martin Whitaker, following the previously successful Phase II clinical trial in congenital adrenal hyperplasia."However, these initial results confirm the concept of Chronocort, that early morning control of androgens can be achieved with a modified release preparation of hydrocortisone."Diurnal will now analyse the full data set from this trial, along with interim data from the ongoing Chronocort long-term dosing study, to determine next steps in the drug's development and discuss these with the regulatory authorities."We remain confident that Chronocort will be a valuable treatment option for CAH patients," Whitaker said.Diurnal, in which IP Group is a major shareholder, recently bagan a Phase III study in congenital adrenal hyperplasia in the USA, focussed particularly on morning control of androgens.

More News

25 Jul 2018 09:39

IP Group Swings To Loss In First-Half On Reduction In Portfolio Gains

LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.The intellectual property-based to

18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

3 Apr 2018 16:19

Diurnal To Raise GBP10.5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said on Tuesday that it intends to raise GBP10.5 million through the placing of different types of shares.The

20 Mar 2018 18:28

Diurnal Nets GBP500,000 From Broker Option Exercise (ALLISS)

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Tuesday said that it has received a letter of notice to exercise the broker option in respect of 263,157 in

12 Mar 2018 13:51

UPDATE: Diurnal Prepares For First Revenue As Appoints Trial Partner

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Monday appointed a clinical trial services provider for its Chronocort treatment, as it posted a widened loss

12 Mar 2018 10:18

Diurnal Interim Loss Widens On Cost Rise As Prepares For First Revenue

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Monday its interim loss widened amid a rise in research and administrative expenses, as it prepares to its

12 Mar 2018 05:17

UK Stocks-Factors to watch on March 12

March 12 (Reuters) - Britain's FTSE 100 index is seen opening up 8 points higher at 7,233 on Monday, according to financial bookmakers. * GKN-MELROSE: GKN has struck a deal

25 Jan 2017 09:31

Diurnal Agrees Two Deals With UDG Healthcare Ahead Of Infacort Launch

17 Jan 2017 15:43

DIRECTOR DEALINGS: Diurnal Non-Executive Ups Interest

16 Jan 2017 15:08

Director dealings: Diurnal trio dip in after EMA submission in December

(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year. Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a pri

12 Jan 2017 09:04

Diurnal Hires Outgoing Mereo BioPharma Finance Chief Bungay

20 Dec 2016 12:23

Diurnal Submits European Marketing Application For Infacort

21 Nov 2016 09:32

Diurnal Doses First Testosterone Replacement Therapy Trial Patients

5 Oct 2016 15:09

UK Earnings, Trading Statements Calendar - Next 7 Days

11 Jul 2016 08:00

Diurnal and IP Group eye 2017 launch for childhood hormonal treatment

(ShareCast News) - Diurnal Group, 45%-owned by university spin-out specialist IP Group, has produced positive clinical trial results for its treatment for a rare hormonal disease in young children. A European Phase III study for AIM-quoted Diurnal's Infacort treatment for paediatric Adrenal Insuffic

Latest Share Chat

DNL.L Share News (DNL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Diurnal's endocrine drug does not meet trial objective

Login to your account

Quickpicks are a member only feature

Login to your account